Zhaohui Wang, DVM, MA

Publications

• Wang, Z., Yoeli, D., Nakra, N., Huang, J., Li, B., Wang, Y., ... & Huang, C. A. (2022). 422.2: Investigating Galectin-3 as a Novel Therapeutic Target To Block Inflammation and Reduce Ischemia Reperfusion Injury During Vascular Composite Allograft Transplantation. Transplantation, 106(9S), S455.
• Wang, Z., Li, B., Wang, Y., Yoeli, D., Nakra, N., La Rosa, D., ... & Huang, C. A. (2022, June). Circulating Galectin-3 Levels Increase in Syngeneic Rat Recipients of Vascularized Composite Allografts Subjected to Prolonged Ischemia. In AMERICAN JOURNAL OF TRANSPLANTATION (Vol. 22, pp. 632-633). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
• MHSRS-22-07596 - POSTER SESSION 2 - #243 Galectin-3 Blockade Reduces Macrophage Infiltration Associated with Ischemia Reperfusion Injury in a Rat Hind Limb Transplant Model
• Qiu, Y., Qi, Z., Wang, Z., Cao, Y., Lu, L., Zhang, H. ... Wang, Z. (2023). EGF-IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. Oncology Reports, 49, 37. https://doi.org/10.3892/or.2022.8474
• CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma
• Wang, Z., Ma, J., Zhang, H., Ramakrishna, R., Mintzlaff, D., Mathes, D. W., Pomfret, E. A., Lucia, M. S., Gao, D., Haverkos, B. M., & Wang, Z. (2023). CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS open bio, 13(7), 1309–1319. https://doi.org/10.1002/2211-5463.13625
• Yoeli, D., Mack, C. L., Luo, Y., Chaidez, A., De La Rosa, N. L., Wang, Z., Cervantes-Alvarez, E., Huang, C. A., & Navarro-Alvarez, N. (2023). Galectin-3 in biliary atresia and other pediatric cholestatic liver diseases. Hepatology research : the official journal of the Japan Society of Hepatology, 10.1111/hepr.13987. Advance online publication. https://doi.org/10.1111/hepr.13987
• Investigating galectin-3 as a novel therapeutic target to block inflammation and reduce ischemia reperfusion injury during vascular composite allotransplantation
• Investigating galectin-3 as a novel therapeutic target to block inflammation and reduce ischemia reperfusion injury during vascular composite allotransplantation
• A Porcine Vascularized Composite Allotransplantation Model for Assessing Early Prognostic Biomarkers of Rejection
• A Porcine Vascularized Composite Allotransplantation Model for Assessing Early Prognostic Biomarkers of Rejection